当前,关于HER2低表达是否可以被确定为一个单独的亚型,目前尚存在争议,可能影响该人群的治疗决策和预后。近日,一项发表在Breast Cancer Research and Treatment的研究探究了HER2低表达状态对早期激素受体(HR)阳性和三阴性乳腺癌(TNBC)患者接受新...
[16]Rossi V, Sarotto I, Maggiorotto F, Berchialla P, Kubatzki F, Tomasi N, et al.. Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early ...
Interventional, Multicenter Study of Trastuzumab Deruxtecan Monotherapy in Patients With Unresectable and/or Metastatic HER2-Low or HER2 Immunohistochemistry 0 Breast Cancer: DESTINY-Breast15. Cancer Res 1 May 2024; 84 (9_Supplement): PO2–19–06. ...
HER2-negative diseaseHormone receptor-negative diseaseChemotherapyBiological agentsMetastatic breast cancer (MBC) remains a challenging disease to treat with only a small minority of patients achieving long-term survival. Although great strides have been made in the fight against breast cancer, ...
[4]Palmieri, Carlo et al. “Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel ...
Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of...
Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which endocrine therapy resistance and distant relapse remain unmet challenges. Accurate molecular classification is urgently required for guiding pre...
Alpelisib(Piqray) is a P13K inhibitor in pill form that can be used with fulvestrant in women with advanced HR+, HER2-negative breast cancer with a PIK3CA gene mutation. Sacituzumab govitecan(Trodelvy) is a monoclonal antibody with an attached chemotherapy drug. It is used to treat some adva...
[25]Corti C, De Angelis C, Bianchini G, et al. Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?[J]. Cancer Treatment Reviews, 2023, 117: 102569. 编辑:River 审校:Max 排版:KIKI 执行:Aurora ...
aAmong triple-negative breast cancers, HER2(0) breast cancer shows a strong tendency to be basal-like compared with HER2(1+) breast cancer: preliminary results. 在三倍消极乳腺癌之中, HER2( 0) 乳腺癌显示一个强的倾向是基础象比较HER2( 1+) 乳腺癌: 初步结果。[translate]...